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SUMMARY
Rheumatoid arthritis may sometimes present with extra-articular involvement, 
pulmonary involvement is not common. Rheumatoid arthritis has been reported among 
Nigerians and extra-articular manifestations are rarely seen. One of the patients was 
misdiagnosed and mismanaged as a patient with pulmonary tuberculosis. The study is 
to demonstrate that rheumatoid arthritis is not as rare as previously reported in Nigeria 
and its pulmonary involvement can mimic tuberculosis or other granulomatous lung 
disorder. Clinical and serological acumen are necessary to distinguish between the two.
Two diagnosed patients with rheumatoid arthritis and pulmonary involvement seen 
at Olabisi Onabanjo University Teaching Hospital (OOUTH), are hereby presented.
INTRODUCTION
Rheumatoid arthritis are not commonly reported in 
Nigeria. There had been community based report 
which emphasised the rarity of rheumatoid arthritis 
as well as extra-articular manifestations (1). A recent 
study by Adelowo et al, gave a contrary result that 
Rheumatoid Arthritis may not be uncommon in 
Nigerians but confirms a low incidence of extra-
articular manifestation and absence of pulmonary 
involvement in 200 patients studied (2).
 Rheumatoid arthritis is usually diagnosed using 
the American College of Rheumatology Criteria (3) 
which has a high sensitivity and specificity. While 
rheumatoid factor are mostly associated with the 
extra-articular manifestation they are mostly negative 
among Africans with Rheumatoid arthritis without 
extra-articular features (4).
 Various pulmonary manifestations have been 
reported in the developed world, these include diffuse 
interstitial fibrosis, pleural effusion, nodular lung 
disease, pulmonary vasculitis, alveolar haemorrhage, 
and pneumonitis (5).
 Two cases seen in the chest unit of medicine 
department, OOUTH are presented as follows:
CASE 1
Mrs A.A was a 55 year old, non-smoking woman 
who presented with a six month history of cough 
productive of yellowish sputum. She had previously 
been diagnosed as arthritic by her general practitioner 
and had been placed on NSAIDs. She was also placed 
on anti-Koch’s which had not made her symptoms 
better.
 Review at the clinic showed that she had a three 
year history of polyarthritis involving joints of the 
hands, elbows, shoulders, knees and ankles. She also 
complained of significant morning joint stiffness.
 Physical examination showed a middle aged 
woman afebrile, pale and dyspnoeic. Cardiovascular 
system revealed pulse of 70bpm, BP 110/70 mmHg, 
Apex beat not displaced, heart sounds I, II and normal.
 Respiratory system examination revealed 
rate of 30 cpm, reduced chest excursion bilaterally, 
breath sounds reduced bilaterally and there were 
fine crepitations in both lung fields especially at the 
bases.
 Musculoskeletal system revealed painful 
swelling of both wrists, ankles and knee joints. 
Tenderness in both metacarpophalangeal joints, 
shoulders and elbow. There was subcutaneous nodule 
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at the left elbow.
A diagnosis of rheumatoid arthritis was made based 
on the ACR criteria. 
 Chest x-ray showed widespread fibrosis of both 
lung fields. ESR was elevated 90min/hr( Westergren) 
rheumatoid factor positive in titre of 1:32. The lung 
function test showed a restrictive pattern: FEV11.5L/
min, FVC1.8L/min with a ratio of FEV1 /FVC 83%. 
PEFR 250ml/min.
 She was placed on sulfasalazine 500mg tds, tab 
prednisolone 15 mg daily and diclofenac as required. 
She was stable and followed up.
CASE 2
Mrs O.D. was a 59 year old woman, nonsmoker who 
had previously presented to the clinic four years ago 
and had been diagnosed with rheumatoid arthritis 
using the ACR criteria. She had been on methotrexate 
tablets 15 mg once weekly and prednisolone with 
occasional NSAIDs. She however defaulted for one 
year before this presentation. She presented again 
in the chest clinic with a dry cough associated with 
breathlessness which had been worsening and 
associated with increasing incapacitation. The cough 
then became minimally productive of yellowish 
sputum.
 Physical examination showed a wasted ill 
looking woman, pale and breathless. Cardiovascular 
examination was essentially normal. Chest 
auscultation showed presence of fine crepitations at 
the lung bases.
 Musculoskeletal system examination revealed 
tenderness in both elbows and shoulders. She also 
had a boggy swelling in the left knee (effusion) and 
few swollen MCP joints. There were no subcutaneous 
nodules. Other systems were essentially normal. 
Laboratory investigations showed elevated ESR 
68ml/hr. positive rheumatoid factors at titer of 1:64.
 Lung function test showed a restrictive pattern 
FEV1 1.6L/min, FVC 1.9L/min,FEV1/FVC 84.2%, 
PEFR 260L/min. Chest X-ray showed widespread 
fibrosis of both lung fields.
 Methotrexate was withheld and was placed on 
methylprednisolone and cyclophosphamide for three 
months. She improved considerably. A repeat CXR 
showed less streakiness in the lung fields. She was 
also placed on flucloxacillin.
DISCUSSION
The reported cases are rare clinical condition of 
pulmonary manifestations of rheumatoid arthritis. 
Diffuse interstitial fibrosis has been described 
in approximately 40% of patients with RA (5-7).
The disorder is initially characterised by chronic 
inflammatory changes in the alveolar walls and the 
presence of large mononuclear cells in the alveolar 
spaces. As the disease progresses, there is tendency 
to fibrosis with obliteration of the alveoli (7) and 
dilatation of the brochiole (8,9). The pulmonary 
areas primarily affected are the base of the lungs in 
the early stage of the disease and apices of the lung 
in more advanced stage.
 Diffuse interstitial fibrosis occurs mostly in 
patients who have subcutaneous nodules and high 
titers of rheumatoid factor (5, 6, 7). The patients in 
question have high titers of rheumatoid factors and 
first patient has subcutaneous nodules. Symptoms 
include progressive dyspnea on exertion and a 
productive cough. The reported patients have 
productive cough and mild dyspnea on exertion.
 Examination of affected patients can reveal an 
increased respiratory rate, clubbing, and crepitations 
particularly at the lung bases (8, 10).
 Chest radiographs typically showed a reticulated 
pattern with progress to a fine nodularity and 
honeycomb fibrosis (11). The CXR of both patients 
showed widespread reticular pattern (fibrosis) with 
some scattered honeycomb appearance in the first 
patient.
 Therapeutic success depends on the amount 
of active inflammation or fibrosis present when 
treatment begins and also on availability of new 
proven effective treatment modalities (12).
 Diffuse pulmonary fibrosis in patients with 
rheumatoid arthritis in the absence of other known 
causes especially infective like Tuberculosis in our 
own environment is suggestive of rheumatoid lung. 
CXR is still the commonest means of diagnosis 
though recent reports have indicated that HRCT is 
more effective (13). This is however not available 
in our hospital. Lung biopsy is rarely indicated 
now. An evidence of erosive arthropathy is highly 
suggestive. Spirometry in rheumatoid lung can either 
be obstructive in the early phase or restrictive in the 
late phase as in the cases discussed. Gas transfer 
factor is diminished in rheumatoid lung except in 
those with alveolar haemorrhage. Protease inhibitor 
phenotype, HLA type, is also important. Rheumatoid 
lung is common in patients with HLA DRB1, those 
with PiMM protease inhibitor phenotype and those 
with tyrosine-phosphatase gene PTPN 22 (14, 
15). Strongest susceptibility factor  has been HLA 
DRB1*0404, however the marker for susceptibility 
to lung disease in rheumatoid arthritis is HLA B40 
(14,15).
 Medications typically given to patients with 
RA and interstitial fibrosis include corticosteroids, 
and other immune modulating agents such as 
sulfasalazine, hydroxychloroquine, cytotoxics like 
Azathioprim, cyclophosphamide, penicillamine and 
gold salts (5, 12, 16). Antibiotics are added to the 
treatment of patients with rheumatoid lung and chest 
infection. Patients with nodular lung needs repeated 
biopsies and monitoring of nodules for early detection 
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of malignant transformation. Because of association of 
methotrexate with pulmonary fibrosis, patients with 
rheumatoid lung must not be given methotrexate (16).
 New treatment strategies in rheumatoid arthritis/ 
rheumatoid lung are targeted to interfere with critical 
inflammatory mediators like interleukin-1 beta and 
tumor necrosis factor α. Patients can be treated with 
intravenous TNF-α Inhibitor (infliximab). There is a 
reported sustained improvement in joint symptoms 
likewise (17, 18). Since April 2002, a recombinant 
human interleukin-1 receptor antagonist (Anakinra) 
is available in Germany (19).
 Antioxidants such as selenium and Vitamin 
E as well as flavonoids can exhibit a novel 
anti-inflammatory action via the Complement- 
Neutrophils Activation Feedback (CNAF) mechanism 
(20). This may be better than immunosuppressives 
because the later increases the risk of life- threatening 
aspergillus infections (21).
 The new treatment strategy was not administered 
in these patients because of non-availability.
 interstitial fibrosis is poor (22). Therapeutic 
success depends on the amount of active inflammation 
or fibrosis present at treatment initiation and also on 
the availability of new proven effective treatment 
modalities. The biologics- etanercept and rituximab, 
though available (2) were not used for the patients 
because they were not affordable to them.
CONCLUSION
This study highlights a pulmonary manifestation of 
rheumatoid arthritis namely interstitial fibrosis, the 
diagnosis which is made clinically.
 It is also important for clinicians in the tropics 
particularly and world all over to keep an open mind 
when seeing patient with cough, not all cases are 
infective and due to tuberculosis. Connective tissue 
disorders are not common but definitely in existence 
and also affect blacks.
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